Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/10/2025

Vaccination Precautions in Patients with Eczema

Risk Assessment and Rationale

  • Patients with active eczema/atopic dermatitis are at increased risk for developing eczema vaccinatum, a potentially life-threatening complication of vaccinia (smallpox) vaccination, according to the Advisory Committee on Immunization Practices (ACIP) 1, 4
  • The ACIP explicitly states that vaccinia vaccine should not be administered to persons with eczema of any degree, those with a past history of eczema, or those whose household contacts have active eczema 3, 5
  • This contraindication extends to other acute, chronic, or exfoliative skin conditions which might also increase risk for serious vaccine complications 2, 6

Complications of Vaccination During Eczema Flare

  • Eczema vaccinatum (EV) is a localized or generalized papular, vesicular, or pustular rash that can occur anywhere on the body, with predilection for areas of previous atopic dermatitis lesions, and is often accompanied by fever and lymphadenopathy 8, 7
  • Historical data showed mortality from EV was 30%-40% before the introduction of vaccinia immune globulin (VIG) 7

Management Recommendations

  • Postpone vaccination until the eczema flare has completely resolved, as recommended by the ACIP 1, 2, 3
  • Ensure the skin condition is well-controlled and in remission before vaccination, considering the risk-benefit ratio of each specific vaccine individually 3, 5

Special Considerations

  • Vaccinia vaccine should not be administered to individuals whose household contacts have active eczema or a history of eczema, to prevent secondary transmission of vaccine virus to vulnerable individuals 1, 10
  • Approximately 30% of eczema vaccinatum cases reported in historical studies were a result of contact transmission from recently vaccinated individuals 1, 9

REFERENCES